07.12.2018 • News

Covestro Completes Share Buyback

Covestro Completes Share Buyback (c) Covestro
Covestro Completes Share Buyback (c) Covestro

A year earlier than planned, German engineering plastics producer Covestro has completed a buyback of company shares worth €1.5 billion, or 10% of its capital stock. The Leverkusen-based former Bayer subsidiary said that the 19.5 million shares repurchased will be retired and the capital reduced accordingly.

The company’s managing board plans to propose a new authorization to acquire treasury shares at an amount of up to 10% of the capital stock at its annual general meeting next year.

Chief Financial Officer Thomas Toepfer said the objective of the buyback program was to create value for shareholders, and this remains the company’s priority.

In view of recent negative reports from the German stock market, Covestro many need to be even more inventive in supporting its share price. In an environment generally less than favorable to chemical companies, the papers of the engineering plastics producer and the many times larger BASF have been bringing up the rear in terms of performance.

On the same day that BASF’s new CEO Martin Brudermüller presented the German chemical giant’s new strategy for the future, which was not enthusiastically received by all investors, Covestro announcedit was revising its outlook for 2018 downward.

The company cited intense competition, a downhill curve for isocyanates prices and low water levels in the Rhine river that hindered shipping, factors similar to those dogging BASF. Shares in Bayer have also disappointed, as investors fear fallout from the more than 9,000 still pending lawsuits involving Monsanto’s glyphosate-based herbicide Roundup.

Covestro now expects volume growth in the low single-digit percentage range and a slightly lower EBITDA compared with 2018.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read